Mid-Size Japanese Pharmas Turn To U.S. Market For Sales Growth
This article was originally published in PharmAsia News
Executive Summary
Some of Japan's smaller drug makers are following their larger colleagues in seeking new or expanded markets in the United States to offset lagging sales growth at home. Dainippon Sumitomo Pharma is developing its lurasidone now in Phase III trials for the U.S. market, beginning with approval to treat schizophrenia in 2012 and later for depression. Mitsubishi Tanabe Pharma and Shionogi also are looking to the U.S. market for sales. The former plans to apply next year for its drug to treat a kidney failure symptom, while the latter seeks to market an appetite suppressant in 2012. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.